The abstract is read at the publisher; the summary is JClub's.
Epcoritamab plus 6-cycle R-CHOP in newly diagnosed CD20+ LBCL with IPI 3–5 achieved a 98% investigator-assessed overall response rate and 85% complete response rate.
- Why it matters: R-CHOP outcomes are inferior for newly diagnosed LBCL patients with IPI scores of 3 to 5, leaving a need for more effective regimens with manageable safety.
- What they did: In arm 1 of the phase 1b/2 EPCORE NHL-2 trial, 47 adults received fixed-duration epcoritamab with R-CHOP for 1 year total; endpoints included ORR, CR, PFS/OS, MRD negativity, and safety.
- The result: At 44.2 months median follow-up, 2-year PFS and OS were 80% and 87%, MRD negativity reached 100% among evaluable patients, and common toxicities included neutropenia (74%), anemia (72%), and CRS (60%).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.